デフォルト表紙
市場調査レポート
商品コード
1435718

ブランドジェネリックの世界市場レポート2024

Branded Generics Global Market Report 2024

出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.74円
ブランドジェネリックの世界市場レポート2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2~10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

ブランドジェネリックの市場規模は、今後数年間で急速に成長すると予想されています。 2028年には10.2%の年間複合成長率(CAGR)で5,423億2,000万米ドルに成長すると予想されます。次期に予想される成長は、ジェネリック生物製剤の需要の高まり、慢性疾患の有病率の増加、新興国市場の拡大、およびバイオシミラー製品への注力に関連しています。この予測期間に予想される主な動向には、戦略的パートナーシップとコラボレーション、技術の進歩、慢性疾患管理への集中的な焦点、市場の統合、患者中心のアプローチへの強い取り組みが含まれます。

慢性疾患の急増により、ブランドジェネリック市場の拡大が促進されると予想されます。これらの永続的な病気は、多くの場合不治ですが管理可能ですが、喫煙、悪い食生活、座りっぱなしの生活、過度のアルコール摂取などの要因により増加しています。標準薬と比較した費用対効果の高さに魅力を感じ、慢性疾患の治療にブランドジェネリックを好む人が世界中で増えています。この傾向を強調して、世界保健機関(WHO)は2022年 9月、世界中で4,100万人の死亡者が報告され、これは年間の非感染性疾患(NCD)による死亡者数全体の74%に相当します。この慢性疾患の急増により、近い将来、ブランドジェネリックの需要が高まると予想されます。

製薬業界におけるニーズの高まりにより、ブランドジェネリック市場の上昇が促進されることになります。医療目的の医薬品の調査、開発、生産、マーケティングに特化したこの業界は、ブランド医薬品の経済的な代替品としてブランドジェネリックに頼っています。さらに、これらのジェネリック医薬品は、製剤がジェネリック医薬品として入手可能な場合でも、使い慣れた信頼できる製品を提供することで、患者の忠誠心を維持するのに役立ちます。特に、2023年6月の欧州製薬産業協会連盟(EFPIA)によると、欧州の医薬品生産は2022年に3,842億米ドル(3,400億ユーロ)に達し、前年比4.95%増加しました。この医薬品需要の急増がブランドジェネリック市場の成長を支えています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年~2023年
  • 世界の市場規模予測と成長、2023年~2028年、2033年

第6章 市場セグメンテーション

  • 世界のブランドジェネリック市場、薬剤クラス別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • アルキル化剤
  • 代謝拮抗物質
  • ホルモン
  • 降圧剤
  • 脂質低下薬
  • 抗うつ薬
  • 抗精神病薬
  • 抗てんかん薬
  • その他の薬剤
  • 世界のブランドジェネリック市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 外用
  • 経口
  • 非経口
  • その他の投与経路
  • 世界のブランドジェネリック市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 腫瘍学
  • 心血管疾患
  • 糖尿病
  • 神経内科
  • 消化器疾患
  • 皮膚科の病気
  • 鎮痛剤および抗炎症剤
  • その他の用途

第7章 地域および国の分析

  • 世界のブランドジェネリック市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
  • 世界のブランドジェネリック市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • ブランドジェネリック市場の競合情勢
  • ブランドジェネリック市場の企業プロファイル
    • Pfizer Inc.
    • F. Hoffmann-La Roche AG
    • Sanofi SA
    • AstraZeneca plc
    • GlaxoSmithKline plc

第31章 その他の大手および革新的な企業

  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Alkem Laboratories Ltd.
  • Mylan NV
  • Sandoz International GmbH
  • Bausch Health Companies Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Ltd.
  • Aurobindo Pharma Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Apotex Inc.
  • Aspen Pharmacare Holdings Limited
  • Endo International plc
  • Towa Pharmaceutical Co. Ltd.
  • Mankind Pharma

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r15428

Branded generics denote unregistered medications marketed under a specific brand name, offering distinct advantages to patients and healthcare providers, fostering brand preference. They encompass generic drugs distinguished by a unique brand identity and may be promoted akin to branded medications.

Branded generics encompass several drug classes, such as alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid-lowering drugs, anti-depressants, anti-psychotics, anti-epileptics, and others. Alkylating agents within branded generics are a subset of anticancer medications that impede DNA-to-RNA conversion, effectively disrupting protein synthesis. These chemicals modify hydrogen atoms on DNA to alkyl groups, inducing cross-links within the DNA strand, leading to cytotoxic, mutagenic, and carcinogenic effects. Branded generics offer various administration routes including topical, oral, parenteral, and others. They cater to diverse medical conditions encompassing oncology, cardiovascular diseases, diabetes, neurology, gastrointestinal ailments, dermatological conditions, analgesics, anti-inflammatory treatments, and more.

The branded generics market research report is one of a series of new reports from The Business Research Company that provides branded generics market statistics, including branded generics industry global market size, regional shares, competitors with a branded generics market share, detailed branded generics market segments, market trends and opportunities, and any further data you may need to thrive in the branded generics industry. This branded generic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The branded generics market size has grown strongly in recent years. It will grow from $335.98 billion in 2023 to $367.67 billion in 2024 at a compound annual growth rate (CAGR) of 9.4%. Historical growth was driven by factors such as cost efficiencies, patent expirations, market reach expansion, government-driven initiatives, and healthcare policy reforms.

The branded generics market size is expected to see rapid growth in the next few years. It will grow to $542.32 billion in 2028 at a compound annual growth rate (CAGR) of 10.2%. Anticipated growth in the upcoming period is linked to heightened demand for generic biologics, the increasing prevalence of chronic illnesses, expanding markets in emerging economies, and a dedicated emphasis on biosimilar products. Key trends expected in this forecast period comprise strategic partnerships and collaborations, technological advancements, a concentrated focus on chronic disease management, market consolidation, and a strong commitment to a patient-centric approach.

The burgeoning prevalence of chronic diseases is anticipated to fuel the expansion of the branded generics market. These enduring ailments, often incurable but manageable, are on the rise due to factors such as tobacco use, poor dietary habits, sedentary lifestyles, and excessive alcohol consumption. The global populace increasingly favors branded generics for treating chronic conditions, attracted by their cost-effectiveness compared to standard medications. Highlighting this trend, in September 2022, the World Health Organization (WHO) reported 41 million deaths worldwide, representing 74% of all noncommunicable disease (NCD) fatalities annually. This upsurge in chronic diseases is poised to elevate the demand for branded generics in the foreseeable future.

The escalating need within the pharmaceutical sector is set to propel the ascent of the branded generics market. This industry, dedicated to drug research, development, production, and marketing for medical purposes, leans on branded generics as an economical alternative to branded drugs. Additionally, these generics help sustain patient loyalty by offering a familiar, trusted product, even when the formulation is available as a generic. Notably, as per the European Federation of Pharmaceutical Industries and Associations (EFPIA) in June 2023, the pharmaceutical production in Europe reached $384,200 million (€340,000 million) in 2022, marking a 4.95% increase from the previous year. This surge in pharmaceutical demand underpins the growth of the branded generics market.

In December 2021 witnessed Biocon Ltd., an India-based biopharmaceutical entity, forging a strategic alliance with Tabuk Pharmaceuticals. This collaboration marks Biocon's foray into the MENA region encompassing Jordan, Lebanon, Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, Oman, and Iraq. The intent behind this partnership is to curate an extensive global product portfolio aimed at providing cost-effective treatments to patients worldwide. Tabuk Pharmaceuticals, rooted in Saudi Arabia, will take charge of marketing authorization, registration, importation, and promotion of these medications within Saudi Arabia and adjoining Middle Eastern countries.

In June 2022, Dr. Reddy's Laboratories, a prominent Indian pharmaceutical firm specializing in branded generics, completed the acquisition of branded and generic injectable products from Eton Pharmaceuticals, Inc., a US-based pharmaceutical company. This transaction, valued at $50 million, serves Dr. Reddy's Laboratories' strategic agenda to expedite and broaden the availability of affordable medications. The acquisition includes notable products such as Biorphen (phenylephrine hydrochloride) injection and Rezipres, augmenting their efforts to introduce biosimilars into the market.

In July 2021, Lupin, an India-based pharmaceutical company offering branded and generic formulations, biosimilars, and active pharmaceutical ingredients (APIs), acquired Southern Cross Pharma Pvt Ltd (SCP) for an undisclosed amount. Through this acquisition, Generic Health, an Australia-based wholly-owned subsidiary of global pharma major Lupin Limited, will have access to more than 60 registered products with approximately USD 22 million in sales. It will result in the growth of value offer and market share of Lupin in the Australian market. Southern Cross Pharma Pvt Ltd (SCP) is an Australia-based pharmaceutical company engaged in developing, registering, and distributing generic products.

Major companies operating in the branded generics market report are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Viatris Inc., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Mylan N.V., Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Apotex Inc., Aspen Pharmacare Holdings Limited, Endo International PLC, Towa Pharmaceutical Co. Ltd., Mankind Pharma, Glenmark Pharmaceuticals, Par Pharmaceuticals Inc., Unichem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Wockhardt, Intas Pharmaceuticals Ltd., Novartis International AG, Novo Nordisk A/S, Zydus Lifesciences Ltd.

North America was the largest region in the branded generics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the branded generics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The branded generics market consists of sales of glucophage, lopressor, and trimox. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Branded Generics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on branded generics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for branded generics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The branded generics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Drug Class: Alkylating Agents; Antimetabolites; Hormones; Anti-hypertensive; Lipid Lowering Drugs; Anti-depressants; Anti-psychotics; Anti-Epileptics; Other Drugs
  • 2) By Route of Administration: Topical; Oral; Parenteral; Other Routes of Administration
  • 3) By Application: Oncology; Cardiovascular Diseases; Diabetes; Neurology; Gastrointestinal Diseases; Dermatology Diseases; Analgesics and Anti-inflammatory; Other Applications
  • Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Sanofi SA; AstraZeneca plc; GlaxoSmithKline plc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Branded Generics Market Characteristics

3. Branded Generics Market Trends And Strategies

4. Branded Generics Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Branded Generics Market Size and Growth

  • 5.1. Global Branded Generics Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Branded Generics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Branded Generics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Branded Generics Market Segmentation

  • 6.1. Global Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Alkylating Agents
  • Antimetabolites
  • Hormones
  • Anti-hypertensive
  • Lipid Lowering Drugs
  • Anti-depressants
  • Anti-psychotics
  • Anti-Epileptics
  • Other Drugs
  • 6.2. Global Branded Generics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Topical
  • Oral
  • Parenteral
  • Other Routes of Administration
  • 6.3. Global Branded Generics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oncology
  • Cardiovascular Diseases
  • Diabetes
  • Neurology
  • Gastrointestinal Diseases
  • Dermatology Diseases
  • Analgesics and Anti-inflammatory
  • Other Applications

7. Branded Generics Market Regional And Country Analysis

  • 7.1. Global Branded Generics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Branded Generics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Branded Generics Market

  • 8.1. Asia-Pacific Branded Generics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Branded Generics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Branded Generics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Branded Generics Market

  • 9.1. China Branded Generics Market Overview
  • 9.2. China Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Branded Generics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Branded Generics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Branded Generics Market

  • 10.1. India Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Branded Generics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Branded Generics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Branded Generics Market

  • 11.1. Japan Branded Generics Market Overview
  • 11.2. Japan Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Branded Generics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Branded Generics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Branded Generics Market

  • 12.1. Australia Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Branded Generics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Branded Generics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Branded Generics Market

  • 13.1. Indonesia Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Branded Generics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Branded Generics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Branded Generics Market

  • 14.1. South Korea Branded Generics Market Overview
  • 14.2. South Korea Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Branded Generics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Branded Generics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Branded Generics Market

  • 15.1. Western Europe Branded Generics Market Overview
  • 15.2. Western Europe Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Branded Generics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Branded Generics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Branded Generics Market

  • 16.1. UK Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Branded Generics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Branded Generics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Branded Generics Market

  • 17.1. Germany Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Branded Generics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Branded Generics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Branded Generics Market

  • 18.1. France Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Branded Generics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Branded Generics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Branded Generics Market

  • 19.1. Italy Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Branded Generics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Branded Generics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Branded Generics Market

  • 20.1. Spain Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Branded Generics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Branded Generics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Branded Generics Market

  • 21.1. Eastern Europe Branded Generics Market Overview
  • 21.2. Eastern Europe Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Branded Generics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Branded Generics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Branded Generics Market

  • 22.1. Russia Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Branded Generics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Branded Generics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Branded Generics Market

  • 23.1. North America Branded Generics Market Overview
  • 23.2. North America Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Branded Generics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Branded Generics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Branded Generics Market

  • 24.1. USA Branded Generics Market Overview
  • 24.2. USA Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Branded Generics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Branded Generics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Branded Generics Market

  • 25.1. Canada Branded Generics Market Overview
  • 25.2. Canada Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Branded Generics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Branded Generics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Branded Generics Market

  • 26.1. South America Branded Generics Market Overview
  • 26.2. South America Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Branded Generics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Branded Generics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Branded Generics Market

  • 27.1. Brazil Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Branded Generics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Branded Generics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Branded Generics Market

  • 28.1. Middle East Branded Generics Market Overview
  • 28.2. Middle East Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Branded Generics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Branded Generics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Branded Generics Market

  • 29.1. Africa Branded Generics Market Overview
  • 29.2. Africa Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Branded Generics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Branded Generics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Branded Generics Market Competitive Landscape And Company Profiles

  • 30.1. Branded Generics Market Competitive Landscape
  • 30.2. Branded Generics Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. F. Hoffmann-La Roche AG
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Sanofi SA
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. AstraZeneca plc
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. GlaxoSmithKline plc
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Branded Generics Market Other Major And Innovative Companies

  • 31.1. Viatris Inc.
  • 31.2. Teva Pharmaceutical Industries Ltd.
  • 31.3. Alkem Laboratories Ltd.
  • 31.4. Mylan N.V.
  • 31.5. Sandoz International GmbH
  • 31.6. Bausch Health Companies Inc.
  • 31.7. Sun Pharmaceutical Industries Ltd.
  • 31.8. Cipla Ltd.
  • 31.9. Aurobindo Pharma Ltd.
  • 31.10. Dr. Reddy's Laboratories Ltd.
  • 31.11. Apotex Inc.
  • 31.12. Aspen Pharmacare Holdings Limited
  • 31.13. Endo International plc
  • 31.14. Towa Pharmaceutical Co. Ltd.
  • 31.15. Mankind Pharma

32. Global Branded Generics Market Competitive Benchmarking

33. Global Branded Generics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Branded Generics Market

35. Branded Generics Market Future Outlook and Potential Analysis

  • 35.1 Branded Generics Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Branded Generics Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Branded Generics Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer